news

  • 31 July 2014
    NeoMed Innovation V, an investment fund exclusively focused on companies developing medical products successfully completed its final closing

    NeoMed Management announced that it held a final closing of NeoMed Innovation V L.P. with €92.1 million ($122 million) in committed capital. Investors include the European Investment Fund and a number of returning investors among them Höegh Capital Partners, Argentum and Sedco Capital.

    The Fund will continue NeoMed’s successful, highly selective investment approach of backing few, emerging companies developing medical products, which have the potential to become sustainable, profitable businesses. The concentrated portfolio approach maximizes the impact of profitable exits on fund performance and has resulted in double digit net investment returns (IRRs) to investors in earlier NeoMed funds.

    Since inception in 1997, NeoMed has invested in 38 emerging companies, realized 29 investments and currently holds 9 investment positions of which 3 in companies that have advanced into the commercial growth phase. NeoMed Innovation V has so far made six investments in promising emerging med tech and specialty pharma companies based in Europe and the US.

    Over the last few years, NeoMed has successfully realized investments in PregLem (Switzerland), Vessix Vascular and Volcano Corp (both USA), EUSA Pharma (UK) and most recently Endosense (Switzerland).

    Erik Amble, managing partner of NeoMed Management said: “The final closing of our fifth Fund at about the same size as our last fund with strong support from returning NeoMed investors, the EIF and several new investors is a major milestone. It enables NeoMed Management to continue to pursue its well proven investment approach and to maintain its position as a leading European based venture capital firm specialized in the international healthcare and medical products industry. NeoMed’s experienced investment team is well positioned to cover the most important regions where innovations in the medical products industry occur.”